Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.54% | -24.46% | -1.57% | 14.60% | 18.26% |
| Total Depreciation and Amortization | 3.31% | -20.53% | -3.06% | -8.41% | -49.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -637.48% | 108.80% | -81.83% | -320.31% | -150.23% |
| Change in Net Operating Assets | -47,683.82% | 99.71% | -127.49% | -183.86% | -2,352.74% |
| Cash from Operations | -71.05% | 31.81% | -33.22% | -6.61% | 6.76% |
| Capital Expenditure | -422.22% | 97.48% | -527.19% | -208.11% | -1,750.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.75% | -32,369.64% | 101.15% | -290.85% | 13.64% |
| Cash from Investing | -13.77% | -94,398.12% | 100.39% | -291.22% | 13.56% |
| Total Debt Issued | -85.42% | 143.38% | -73.17% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.35% | 889.02% | 72.27% | 12.80% | 2,914.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.03% | -- | 100.00% | -- | -- |
| Cash from Financing | -31.15% | 1,269.37% | -72.70% | 67,045.50% | 2,914.29% |
| Foreign Exchange rate Adjustments | -- | -- | -100.00% | -83.33% | 700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -182.04% | 618.84% | -1,224.95% | -147.78% | 176.41% |